significantly lower – Page 12 – Communicable Diseases Research

Evaluation of hematological parameters and inflammatory markers in children with COVID-19

COVID-19 소아의 혈액학적 매개변수 및 염증 표지자 평가

Article

Published on 2022-08-012022-09-11
Journal: Irish Journal of Medical Science [Category] 바이오마커,

Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials

Research article

Published on 2022-08-012022-10-05
Journal: Journal of microbiology, immunology, and infection [Category] 신약개발, 임상, 치료제,

COVID-19 in Children: Correlation Between Epidemiologic, Clinical Characteristics, and RT-qPCR Cycle Threshold Values

Observational Study

Published on 2022-08-012022-10-04
Journal: The Pediatric Infectious Disease Journal [Category] COVID19(2023년), SARS, 임상,

Utility of Newborn Dried Blood Spots to Ascertain Seroprevalence of SARS-CoV-2 Antibodies Among Individuals Giving Birth in New York State, November 2019 to November 2021

2019년 11월부터 2021년 11월까지 뉴욕주에서 출생한 개인들 사이에서 SARS-CoV-2 항체의 혈청유병성을 확인하기 위한 신생아 건조 혈액 반점의 유용성

Article

Published on 2022-08-012022-09-11
Journal: JAMA Network Open [Category] SARS, 진단, 치료기술,

[키워드] 95% CI age analyzed association Birth Birth weight Blood can be used Characteristics collected conducted correlated COVID-19 COVID-19 case COVID-19 vaccination cross-sectional cross-sectional study cumulative DBS sample detect Dried blood spots exposure to female fluctuation gestational age Giving identify IgG antibodies IgG antibody immunoassay individual individuals Infant Infants Low birth weight Lower male maternal age median microsphere MONITOR Multiple birth New York Newborn Odds ratio Older outcome pregnant Prevalence Program reflected repeated reported S antigen SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 N SARS-CoV-2 nucleocapsid SARS-CoV-2 seroprevalence Screening screening program Seroprevalence Serosurvey Serosurveys significantly lower spot state stratified study period submitted utility vaccination Vaccinations was measured women
[DOI] 10.1001/jamanetworkopen.2022.27995 PMC 바로가기 [Article Type] Article

Clinical Effect of Early administration of Tocilizumab Following the Initiation of Corticosteroid Therapy for Patients with COVID-19

Article

Published on 2022-08-012022-10-05
Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome addition administration analyzed baseline blood cell count C-reactive protein caused clinical Clinical characteristics combination therapy coronavirus Corticosteroid corticosteroid therapy corticosteroid treatment Corticosteroids COVID-19 determine drug early administration Effect effective Efficacy evaluated global pandemic groups hospital Hospitalized Initiation maximum body temperature not significantly different oxygen-free day Patient patients with COVID-19 Result SARS-CoV-2 significant decrease significantly higher significantly lower significantly more survival rate Tocilizumab tocilizumab administration treated treating COVID-19 two groups white with COVID-19 Wuhan
[DOI] 10.1016/j.jiac.2022.08.021 [Article Type] Article

Effectiveness of Naturally Acquired and Vaccine-Induced Immune Responses to SARS-CoV-2 Mu Variant

SARS-CoV-2 Mu 변이체에 대한 자연 획득 및 백신 유도 면역 반응의 효과

Article

Published on 2022-08-012022-09-11
Journal: Emerging Infectious Diseases [Category] COVID19(2023년), SARS, 변종,

Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency

Article

Published on 2022-08-012022-11-15
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS, 진단,

[키워드] anti-S IgG antibody association Autoimmunity B-cells baseline CD19 CD4 CD8 Cellular immune response clinical Cohort common common variable immune deficiency coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 mRNA vaccines criteria CVID deficiency develop Diagnosis disease dose expression Frequency HCs humoral IgA IgG IgG deficiency IgG subclasse immune Immune profile immunological characteristics impairment investigated memory Moderna Moderna mRNA vaccine mRNA mRNA vaccine naïve neutralization activity OX40 Patient Pfizer-BioNTech Pfizer-BioNTech mRNA vaccine Poor predicted primary antibody primary antibody deficiency response responses SARS-CoV-2 spike protein Selective IgG subclass deficiency significantly lower Specific Specific antibody deficiency. subset T-cell T-cell Response T-cells vaccination Vaccine vaccine response
[DOI] 10.1007/s10875-022-01296-4 PMC 바로가기

Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections

중환자 환경에서 COVID-19 과염증 환자의 토실리주맙 치료와 병원 획득 세균 및 침습성 진균 감염의 발병률 증가 사이의 연관성

Article

Published on 2022-08-012022-09-12
Journal: The Journal of hospital infection [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료법,

[키워드] 95% CI 95% confidence interval adverse event Bacterial Characteristics COVID-19 COVID-19 mortality COVID-19 secondary infections Critical care elevated Frequency Fungal infection fungal infections greater hospital discharge Hospital stay Hyperinflammatory ICU ICU admission incidence increase in inhibitor intensive care interleukin-6 invasive Invasive mechanical ventilation median Mortality Non-COVID-19 occurred outcome Patient patients with COVID-19 reduce reported retrospective review serious infection severe coronavirus disease severe COVID-19 significantly higher significantly lower Survivors Tocilizumab Treatment
[DOI] 10.1016/j.jhin.2022.04.007 PMC 바로가기 [Article Type] Article

Humoral and cellular responses to mRNA-based COVID-19 booster vaccinations in patients with solid neoplasms under active treatment

Article

Published on 2022-08-012022-10-05
Journal: ESMO open [Category] 진단, 치료법,

[키워드] acute respiratory syndrome anti-spike antibody antibodies baseline BNT162b2 booster booster dose booster vaccination breakthrough infections Cancer cancer patient Cancer patients Care cause CD19+ CD4+ cell counts Cellular immune response cellular immunity cellular response Chemotherapy coronavirus COVID-19 COVID-19 infection died disease dose Efficacy Endocrine evaluated excluded exclusion criteria Factor Factors high risk high-risk population hospital humoral Humoral immunity immune response Immunosuppression immunosuppressive Infection Messenger RNA Mild mRNA mRNA vaccine mRNA-1273 mRNA-based neoplasm neutralizing antibody older patients Other outcome overcome Patient positive reduced required Result severe coronavirus disease significant increase significantly increased significantly lower solid malignancy solid tumors T-cell Response treated Treatment vaccination Vaccine vaccine dose Vaccines were assessed
[DOI] 10.1016/j.esmoop.2022.100587 [Article Type] Article

Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study

COVID-19 폐렴에 감염된 입원 환자의 렘데시비르 치료: 사례-대조군 연구

Observational Study

Published on 2022-08-012022-10-30
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, 치료제,

[키워드] Admission adverse event adverse events affected Analysis analyzed Antiviral antiviral therapy Antiviral treatment baseline characteristics case-control study Clinical outcome clinical outcomes control group coronavirus disease Coronavirus disease 2019 COVID-19 Efficacy Hospitalization hospitalized patient hospitalized patients ICU ICU admission in vitro activity intensive care intensive care unit lower mortality mortality rate Multivariate analysis observational study Odds ratio patients treated Remdesivir reported retrospective risk SARS-CoV-2 severe coronavirus disease significantly lower subject supportive therapies survival survival analysis treated Treatment two groups viruses with COVID-19
[DOI] 10.1002/jmv.27768 PMC 바로가기 [Article Type] Observational Study